We receive many enquiries about participation in our clinical trials. However, we do not accept participants directly through the Small Pharma website or company email addresses. For more information about our clinical trials, please click on the links below. Please note that Small Pharma is not able to diagnose, advise, provide care or make treatment referrals. If you need urgent medical help, please contact the emergency services or your doctor as soon as possible.
SPL026 with supportive therapy Phase I in psychedelic-naive healthy volunteers
SPL026 with supportive therapy Phase IIa in patients with Major Depressive Disorder
London and Liverpool, UK
SPL026 with supportive therapy Phase IIb in patients with Major Depressive Disorder
Multiple sites (global)
Not yet recruiting
Liverpool & Manchester, UK
Ultra-short programs: SPL026 with supportive therapy for Major Depressive Disorder
Small Pharma was awarded an Innovation Passport designation by the MHRA for this program. The designation provides Small Pharma with access to the ILAP (the Innovative Licensing and Access Pathway) which aims to accelerate the time to market for SPL026, facilitating patient access to this potential new treatment.
Phase I: Complete
No. of participants: 32
Indication: Psychedelic naive healthy volunteers
Location: Hammersmith Medical Research, London
Phase IIA: In Progress
Status: In Progress, Recruitment Closed
No. of participants: up to 42
Indication Patients with moderate/ severe Major Depressive Disorder
Location: Hammersmith Medical Research, London and MAC Clinical Research, Liverpool
Phase IIB: Not Actively Recruiting
Status: We are not yet actively recruiting for Phase IIb. We will update this page with details about the sites that will be involved in our Phase IIb trial once they have been approved.
SSRI Drug Interaction Study: Actively Recruiting
This study will assess the interaction between serotonin reuptake inhibitors (SSRIs) and SPL026 with supportive therapy in patients with MDD.
Status: Actively Recruiting
Indication: Patients with moderate/severe MDD
No. of participants: Up to 24
Location: Two MAC Clinical Research sites – Liverpool and Manchester
View Eligibility Requirements: For more information on how to apply to this study CLICK HERE.
Short-acting psychedelic for depression
We are evaluating short acting psychedelics, like SPL026, with supportive therapy as a potential new approach to the treatment of depression.
“It needs to be competitive in public health systems; it needs to be kind of cost-effective. If a more condensed, powerful experience could have therapeutic effects... then it's totally worth exploring.” Dr David Erritzoe, Psychiatrist at Imperial College London
Anticipated treatment journey
Psychedelic therapist training
To support our clinical programs, we run a training program for therapists to support the delivery of short-acting psychedelic therapy protocols, such as with our lead program SPL026.
Designed by experts
Our training program has been designed in collaboration with leading experts in psychedelic therapy methods and approaches.
Our program uses multiple methods including theory, experimental learning and observational work, ensuring therapists feel comfortable and empowered to deliver the protocol in a clinical trial setting.
We are actively recruiting and registering the interest of therapists interested in our training. Successful completion of the therapy training will make you eligible to participate as a therapist in our future clinical trials.
To find out more, or to register your interest in upcoming therapist training programs, please email Dr Tiffanie Benway at: